Project · 2026

Pharma Fundamentals

A research dashboard for thirteen of the largest US-listed pharmaceutical and biotechnology companies. A decade of financial statements from SEC EDGAR, read side by side with what management says about its pipeline, approvals and risks, every passage linked to the filing it came from.

Role Sole designer and builder Stack Python, SQLite, Chart.js Data SEC EDGAR (XBRL, 10-K, 10-Q)

01 Overview

The numbers, and the story behind them

Drug companies are hard to read from the financials alone. A quarter of strong revenue can sit on top of a patent expiry two years out, and a loss can be the cost of a late-stage trial that changes everything. The numbers matter, but they only make sense next to what the company is developing, what regulators have decided and what management is worried about.

This dashboard puts both in one place for Moderna, Pfizer, AbbVie, Johnson & Johnson, Eli Lilly, Merck, Bristol Myers Squibb, Amgen, Gilead, Vertex, Regeneron, Biogen and Alnylam. Quarterly and annual statements run from 2015 to the third quarter of 2026, with around sixty metrics per company, and a briefing for each company draws verbatim passages from its latest annual and quarterly reports.

Compare up to six companies with consistent colors across every chart, switch between quarterly and annual periods, narrow the year range and export any series to CSV. It runs entirely in the browser, in English or French, light or dark.

In pharma, the income statement shows where a company has been. The filings show where it is trying to go.

02 Inside the dashboard

Six screens, thirteen companies

Captured from the published dashboard. The screens follow the language and theme you are reading in.

Screenshot: Overview: trailing-twelve-month revenue, earnings, free cash flow, R&D intensity and net debt for six companies side by side. Screenshot: Overview: trailing-twelve-month revenue, earnings, free cash flow, R&D intensity and net debt for six companies side by side.
Overview: trailing-twelve-month revenue, earnings, free cash flow, R&D intensity and net debt for six companies side by side.
Screenshot: Income statement: a decade of annual revenue, cost of sales, R&D and SG&A for Eli Lilly, Merck, Pfizer and AbbVie. Screenshot: Income statement: a decade of annual revenue, cost of sales, R&D and SG&A for Eli Lilly, Merck, Pfizer and AbbVie.
Income statement: a decade of annual revenue, cost of sales, R&D and SG&A for Eli Lilly, Merck, Pfizer and AbbVie.
Screenshot: Cash flow: operating cash flow, capital spending, free cash flow and FCF margin, year by year. Screenshot: Cash flow: operating cash flow, capital spending, free cash flow and FCF margin, year by year.
Cash flow: operating cash flow, capital spending, free cash flow and FCF margin, year by year.
Screenshot: Ratios and returns: return on equity, return on assets, ROIC and margins for five large-cap biotechs, quarterly since 2015. Screenshot: Ratios and returns: return on equity, return on assets, ROIC and margins for five large-cap biotechs, quarterly since 2015.
Ratios and returns: return on equity, return on assets, ROIC and margins for five large-cap biotechs, quarterly since 2015.
Screenshot: Balance sheet: total assets, cash, short-term investments and receivables for four serial acquirers. Screenshot: Balance sheet: total assets, cash, short-term investments and receivables for four serial acquirers.
Balance sheet: total assets, cash, short-term investments and receivables for four serial acquirers.
Screenshot: Management and product developments: verbatim excerpts from Pfizer's latest 10-Q, grouped by topic, each linked to its dated SEC source. Screenshot: Management and product developments: verbatim excerpts from Pfizer's latest 10-Q, grouped by topic, each linked to its dated SEC source.
Management and product developments: verbatim excerpts from Pfizer's latest 10-Q, grouped by topic, each linked to its dated SEC source.

Real SEC data as of the snapshot date. Select the center image to open it full size.

03 What it does

Seven tabs, one company or six

What an analyst reaches for when sizing up a drug developer.

Financial statements

Income statement, balance sheet and cash flow as reported, quarterly or annual, from 2015 to the latest quarter, with charts and tables you can export.

R&D and profitability

R&D intensity, gross, operating and net margins, stock compensation and capital spending as a share of revenue, the measures that separate pharma models.

Cash and leverage

Free cash flow, FCF conversion, net debt, debt to equity and the cash, buybacks and acquisitions that show how each company funds its pipeline.

Returns and growth

Return on equity, assets and invested capital, year-over-year growth and a CAGR table across headline line items.

Management & product developments

Five topics per company: management priorities, clinical progress, approvals and regulatory events, products and partnerships, and material risks.

Every claim sourced

Each excerpt shows its form, filing date and period, and links to the original document on SEC EDGAR, with direct links to every recent filing.

04 Under the hood

Extract, never invent

A Python pipeline pulls each company's XBRL facts and filing history from SEC EDGAR, keeps the raw responses compressed in SQLite, and normalizes them into calendar-aligned quarterly and annual series. Fiscal calendars that do not end in December, like Johnson & Johnson's, still line up on the same axis. Where a company reports only the full year, the fourth quarter is derived as the year less its first nine months. Values a company does not tag stay blank rather than being estimated, so a dash in the app always means unavailable, never zero.

A second stage downloads the full 10-K and 10-Q documents into a local archive with a manifest of original URLs, sizes and SHA-256 checksums. From those reports, a deterministic ranking selects up to two passages per topic, favoring recent quarterly disclosures and concrete milestones and filtering out boilerplate accounting text. Nothing is paraphrased or generated. A test confirms that every published excerpt appears word for word in its archived source.

The public build strips local archive links and keeps the SEC URLs, so the hosted site stays a small static snapshot while the full report archive stays offline. The French interface translates navigation and labels, and leaves filing quotations in their original English.

Python SQLite SEC EDGAR XBRL Chart.js Vanilla JS Bilingual UI

The hosted version is a snapshot. Financial data was retrieved from SEC EDGAR on the date shown in the app, and each briefing shows the date of its latest reviewed filing. Values can differ from company presentations because of XBRL tagging, restatements and derived quarters; check original filings before relying on them. Forward-looking statements are management plans, not guaranteed outcomes. Educational use only, not investment advice.

Read the pipeline and the P&L together

The full dashboard is live and interactive. Pick a few companies and compare them.